SRPTSarepta Therapeutics, Inc.同业对比
Sarepta Therapeutics, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SRPT本股 | $2.0B#8 | — | 1.3x#2 | 1.1x#2 | 4.3%#7 | -403.3%#10 | -37.5%#4 | -46.7%#8 | -73.0%#4 | — | -24.2%#8 | — |
| VERA | $2.2B#1 | — | 5.4x#7 | — | — | -96.9%#7 | — | -73.5%#10 | -72.7%#3 | — | 18.5%#6 | — |
| PVLA | $2.2B#2 | — | 10.2x#9 | 51.6x#8 | 65.3%#3 | -139.3%#8 | -90.2%#6 | -19.2%#5 | — | — | 99.0%#2 | — |
| PRGO | $2.2B#3 | — | 0.9x#1 | 0.5x#1 | -2.8%#8 | -729.7%#11 | -26.4%#3 | -56.7%#9 | -20.9%#2 | 4#1 | -18.0%#7 | 7.3%#1 |
| HRMY | $2.2B#4 | 12.0x#1 | 2.2x#4 | 2.5x#3 | 21.5%#6 | 9.1%#6 | 24.0%#1 | 15.9%#1 | 25.5%#1 | 4#1 | 26.2%#5 | — |
| ZYME | $2.1B#5 | — | 26.6x#11 | 20.2x#5 | 38.9%#5 | 33.9%#2 | -87.3%#5 | -100.9%#11 | — | — | 59.5%#3 | — |
| SEPN | $2.0B#6 | — | 5.3x#6 | 44.4x#7 | 4174.5%#1 | 31.9%#3 | -148.6%#7 | -12.6%#3 | — | — | 118.1%#1 | — |
| TRVI | $2.0B#7 | — | 6.1x#8 | — | — | 10.7%#5 | — | -13.3%#4 | — | — | 29.6%#4 | — |
| AGIO | $1.9B#9 | — | 1.8x#3 | 34.5x#6 | 48.0%#4 | -161.3%#9 | -873.9%#8 | -40.3%#7 | — | — | — | — |
| SLS | $1.8B#10 | — | 13.0x#10 | — | -100.0%#9 | 13.0%#4 | — | -19.5%#6 | — | — | — | — |
| STOK | $1.8B#11 | — | 5.0x#5 | 9.6x#4 | 404.5%#2 | 92.3%#1 | -11.2%#2 | -2.0%#2 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议